Actives from MMV Open Access Boxes? A suggested way forward

22 Apr 2021

Samby K, Willis PA, Burrows JN, Laleu B, Webborn PJH

PLOS Pathogens
PMID: 33886696

Doi: 10.1371/journal.ppat.1009384

Photo: Freedom Studio/

It is estimated that more than 1 billion people across the world are affected by a neglected tropical disease (NTD) that requires medical intervention. These diseases tend to afflict people in areas with high rates of poverty and cost economies billions of dollars every year. Collaborative drug discovery efforts are required to reduce the burden of these diseases in endemic regions. The release of "Open Access Boxes" is an initiative launched by Medicines for Malaria Venture (MMV) in collaboration with its partners to catalyze new drug discovery in neglected diseases. These boxes are mainly requested by biology researchers across the globe who may not otherwise have access to compounds to screen nor knowledge of the workflow that needs to be followed after identification of actives from their screening campaigns. Here, we present guidelines on how to move such actives beyond the hit identification stage, to help in capacity strengthening and enable a greater impact of the initiative.

To view the full article please visit the PLOS Pathogens website